Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men
Author:
Izzi-Engbeaya Chioma12ORCID, Jones Sophie1, Crustna Yoshibye1, Machenahalli Pratibha C1, Papadopoulou Deborah12, Modi Manish1, Starikova Jessica1, Chan Derek1, Eng Pei Chia1, Phylactou Maria1, Ratnasabapathy Risheka1, Mills Edouard1, Yang Lisa1, Pacuszka Ewa1, Bech Paul1, Minnion James1ORCID, Tharakan George13, Tan Tricia12ORCID, Veldhuis Johannes4, Abbara Ali12ORCID, Comninos Alexander N12ORCID, Dhillo Waljit S12ORCID
Affiliation:
1. Section of Endocrinology and Investigative Medicine, Imperial College London, London, UK 2. Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK 3. Department of Acute Medicine, Imperial College Healthcare NHS Trust, London, UK 4. Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
Abstract
Abstract
Context
Glucagon increases energy expenditure; consequently, glucagon receptor agonists are in development for the treatment of obesity. Obesity negatively affects the reproductive axis, and hypogonadism itself can exacerbate weight gain. Therefore, knowledge of the effects of glucagon receptor agonism on reproductive hormones is important for developing therapeutics for obesity; but reports in the literature about the effects of glucagon receptor agonism on the reproductive axis are conflicting.
Objective
The objective of this work is to investigate the effect of glucagon administration on reproductive hormone secretion in healthy young men.
Design
A single-blinded, randomized, placebo-controlled crossover study was conducted.
Setting
The setting of this study was the Clinical Research Facility, Imperial College Healthcare NHS Trust.
Participants
Eighteen healthy eugonadal men (mean ± SEM: age 25.1 ± 1.0 years; body mass index 22.5 ± 0.4 kg/m2; testosterone 21.2 ± 1.2 nmol/L) participated in this study.
Intervention
An 8-hour intravenous infusion of 2 pmol/kg/min glucagon or rate-matched vehicle infusion was administered.
Main Outcome Measures
Luteinizing hormone (LH) pulsatility; LH, follicle-stimulating hormone (FSH), and testosterone levels were measured.
Results
Although glucagon administration induced metabolic effects (insulin area under the curve: vehicle 1065 ± 292 min.µU/mL vs glucagon 2098 ± 358 min.µU/mL, P < .001), it did not affect LH pulsatility (number of LH pulses/500 min: vehicle 4.7 ± 0.4, glucagon 4.2 ± 0.4, P = .22). Additionally, there were no significant differences in circulating LH, FSH, or testosterone levels during glucagon administration compared with vehicle administration.
Conclusions
Acute administration of a metabolically active dose of glucagon does not alter reproductive hormone secretion in healthy men. These data are important for the continued development of glucagon-based treatments for obesity.
Funder
Medical Research Council Biotechnology and Biological Sciences Research Council National Institute for Health Research EuroCHIP NIHR Imperial Biomedical Research Centre Wellcome Trust National Health Service
Publisher
The Endocrine Society
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference28 articles.
1. Islet α cells and glucagon—critical regulators of energy homeostasis;Campbell;Nat Rev Endocrinol.,2015 2. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice;Pocai;Diabetes.,2009 3. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents;Finan;Nat Med.,2015 4. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice;Jall;Mol Metab.,2017 5. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study;Ambery;Lancet.,2018
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|